Genomic Expression’s New Breakthrough Technology Enables RNA Tag Sequencing on an Array

Share Article

The digital array is bridging the gap between sequencing and the array platform and can be implemented in the existing laboratory infrastructure without any need to buy new equipment. Applying the technology can dramatically speeds up the development of personalized medicine which holds the promise of delivering better healthcare to everyone at less cost.

Genomic Expression's Digital Array

“The concept is smart, almost genius…. very exciting, with great commercial potential”

Genomic Expression, Inc. has developed a method to perform RNA tag sequencing on a digital array. This has not previously been possible. Called the DNA barcode Technology, this new breakthrough technology can be implemented in the existing laboratory infrastructure without any need to buy new equipment.

The digital array is merging the ease of use of the microarray platform and the quality data that so far has only been provided by expensive and cumbersome sequencing machines.

The DNA barcode technology enables the development of a point-of-care solution the size of an iPhone which is able to identify and analyze biomarkers in unlimited numbers.

The digital arrays have infinite applications; whereas the current analog arrays are custom designed to a specific problem.

The underlying DNA barcode technology can be applied as an application engine for Next Generation Sequencing (NGS). Applications include digital mRNA profiling, methylation profiling and SNP profiling.

This new technology enables a faster and more efficient development of low-cost solutions that can be used as the diagnostic component of personalized medicines.

Genomic Expression dramatically speed up the development of Personalized Medicine which holds the promise of delivering better healthcare to everyone at less cost.

Personalized medicine is not necessarily expensive medicine; it is the ability to deliver the right medicine that is most effective for the individual patient. The key enabler is the diagnostic component.

Each year the US is spending more than $200 billion on drugs of which half is ineffective in the individual patient.

“Genomic Expression can speed up the identification of responders and non-responders and therefore participate in delivering better and more effective healthcare,” says Gitte Pedersen, CEO.

Genomic Expression has initiated projects with key academic partners globally and Gitte Pedersen, CEO, has been speaking at a number of events in New York in September.

The technology was presented for the first time at Beyond the Genome in Boston last week.

Learn more about the DNA barcode technology and get our Scientific Paper here

Genomic Expression's mission is to develop inexpensive discovery and diagnostic tools that make research and predicting patient response to particular drugs more effective and thereby reduce healthcare cost and improve human lives.

# # #

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Gitte Pedersen, CEO
Visit website